# Alzamend Neuro, Inc.: financial statements, quarterly

ALZN · Nasdaq · CIK 1677077 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Apr 30

Pages: [Overview](/companies/alzn.md) · [Financials](/companies/alzn/financials.md) · [Filings](/companies/alzn/filings.md) · [Insiders](/companies/alzn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alzn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [1,997](/filings/0001214659-24-020264.md) | [1,909](/filings/0001214659-25-004123.md) | [183 d](/filings/0001214659-25-010763.md) | [207](/filings/0001214659-25-013609.md) | [311](/filings/0001214659-25-017793.md) | [447](/filings/0001214659-26-003166.md) | [450 d](/filings/0001214659-26-008832.md) | [1,741](/filings/0001214659-26-011572.md) | [176](/filings/0001214659-25-017793.md) | [1,279](/filings/0001214659-26-003166.md) | [434 d](/filings/0001214659-26-008832.md) | [1,086](/filings/0001214659-26-011572.md) |
| Operating income | $k | [(2,902)](/filings/0001214659-24-020264.md) | [(2,660)](/filings/0001214659-25-004123.md) | [(850) d](/filings/0001214659-25-010763.md) | [(962)](/filings/0001214659-25-013609.md) | [(1,358)](/filings/0001214659-25-017793.md) | [(1,037)](/filings/0001214659-26-003166.md) | [(1,139) d](/filings/0001214659-26-008832.md) | [(2,700)](/filings/0001214659-26-011572.md) | [(998)](/filings/0001214659-25-017793.md) | [(2,198)](/filings/0001214659-26-003166.md) | [(2,871) d](/filings/0001214659-26-008832.md) | [(3,025)](/filings/0001214659-26-011572.md) |
| Interest expense | $k | [4.3](/filings/0001214659-24-020264.md) | [2.5](/filings/0001214659-25-004123.md) | [1.5 d](/filings/0001214659-25-010763.md) | [12.0](/filings/0001214659-25-013609.md) | [3.5](/filings/0001214659-25-017793.md) | [2.0](/filings/0001214659-26-003166.md) | [0.5 d](/filings/0001214659-26-008832.md) | [2.5](/filings/0001214659-26-011572.md) | [2.6](/filings/0001214659-25-017793.md) | [1.3](/filings/0001214659-26-003166.md) | [0.2 d](/filings/0001214659-26-008832.md) | [2.0](/filings/0001214659-26-011572.md) |
| Net income | $k | [(2,906)](/filings/0001214659-24-020264.md) | [(2,662)](/filings/0001214659-25-004123.md) | [(852) d](/filings/0001214659-25-010763.md) | [(974)](/filings/0001214659-25-013609.md) | [(1,362)](/filings/0001214659-25-017793.md) | [(1,039)](/filings/0001214659-26-003166.md) | [(1,139) d](/filings/0001214659-26-008832.md) | [(2,703)](/filings/0001214659-26-011572.md) | [(1,001)](/filings/0001214659-25-017793.md) | [(2,199)](/filings/0001214659-26-003166.md) | [(2,870) d](/filings/0001214659-26-008832.md) | [(3,027)](/filings/0001214659-26-011572.md) |
| Diluted EPS | $ per share | [(4.43)](/filings/0001214659-24-020264.md) | [(3.77)](/filings/0001214659-25-004123.md) | not reported | [(11.42)](/filings/0001214659-25-013609.md) | [(3.61)](/filings/0001214659-25-017793.md) | [(1.75)](/filings/0001214659-26-003166.md) | not reported | [(1.28)](/filings/0001214659-26-011572.md) | [(0.30)](/filings/0001214659-25-017793.md) | [(0.58)](/filings/0001214659-26-003166.md) | not reported | [(0.68)](/filings/0001214659-26-011572.md) |
| Basic EPS | $ per share | [(4.43)](/filings/0001214659-24-020264.md) | [(3.77)](/filings/0001214659-25-004123.md) | not reported | [(11.42)](/filings/0001214659-25-013609.md) | [(3.61)](/filings/0001214659-25-017793.md) | [(1.75)](/filings/0001214659-26-003166.md) | not reported | [(1.28)](/filings/0001214659-26-011572.md) | [(0.30)](/filings/0001214659-25-017793.md) | [(0.58)](/filings/0001214659-26-003166.md) | not reported | [(0.68)](/filings/0001214659-26-011572.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [200](/filings/0001214659-23-016500.md) | [283](/filings/0001214659-24-005088.md) | [376](/filings/0001214659-25-010763.md) | [1,194](/filings/0001214659-24-016346.md) | [4,093](/filings/0001214659-24-020264.md) | [3,358](/filings/0001214659-25-004123.md) | [3,949](/filings/0001214659-26-008832.md) | [5,621](/filings/0001214659-25-013609.md) | [4,449](/filings/0001214659-25-017793.md) | [2,713](/filings/0001214659-26-003166.md) | [711](/filings/0001214659-26-011572.md) | [7,591](/filings/0001214659-26-011572.md) |
| Current assets | $k | [782](/filings/0001214659-23-016500.md) | [594](/filings/0001214659-24-005088.md) | [455](/filings/0001214659-25-010763.md) | [1,416](/filings/0001214659-24-016346.md) | [4,767](/filings/0001214659-24-020264.md) | [3,947](/filings/0001214659-25-004123.md) | [4,177](/filings/0001214659-26-008832.md) | [5,929](/filings/0001214659-25-013609.md) | [4,721](/filings/0001214659-25-017793.md) | [3,699](/filings/0001214659-26-003166.md) | [1,764](/filings/0001214659-26-011572.md) | [8,255](/filings/0001214659-26-011572.md) |
| Total assets | $k | [984](/filings/0001214659-23-016500.md) | [783](/filings/0001214659-24-005088.md) | [632](/filings/0001214659-25-010763.md) | [1,670](/filings/0001214659-24-016346.md) | [5,008](/filings/0001214659-24-020264.md) | [4,176](/filings/0001214659-25-004123.md) | [4,603](/filings/0001214659-26-008832.md) | [6,327](/filings/0001214659-25-013609.md) | [5,092](/filings/0001214659-25-017793.md) | [4,042](/filings/0001214659-26-003166.md) | [2,079](/filings/0001214659-26-011572.md) | [8,542](/filings/0001214659-26-011572.md) |
| Current liabilities | $k | not reported | [3,826](/filings/0001214659-24-005088.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total liabilities | $k | [3,666](/filings/0001214659-23-016500.md) | [4,569](/filings/0001214659-24-005088.md) | [3,226](/filings/0001214659-25-010763.md) | [2,882](/filings/0001214659-24-016346.md) | [1,255](/filings/0001214659-24-020264.md) | [726](/filings/0001214659-25-004123.md) | [635](/filings/0001214659-26-008832.md) | [983](/filings/0001214659-25-013609.md) | [717](/filings/0001214659-25-017793.md) | [1,857](/filings/0001214659-26-003166.md) | [1,346](/filings/0001214659-26-011572.md) | [2,739](/filings/0001214659-26-011572.md) |
| Shareholders' equity | $k | [(2,682)](/filings/0001214659-23-016500.md) | [(4,264)](/filings/0001214659-24-005088.md) | [(2,594)](/filings/0001214659-26-003166.md) | [(1,212)](/filings/0001214659-25-017793.md) | [3,753](/filings/0001214659-26-003166.md) | [3,450](/filings/0001214659-26-003166.md) | [3,968](/filings/0001214659-26-011572.md) | [5,343](/filings/0001214659-26-011572.md) | [4,374](/filings/0001214659-26-003166.md) | [2,200](/filings/0001214659-26-008832.md) | [733](/filings/0001214659-26-011572.md) | [5,803](/filings/0001214659-26-011572.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,513) d](/filings/0001214659-24-020264.md) | [(2,032) d](/filings/0001214659-25-004123.md) | [(1,427) d](/filings/0001214659-25-010763.md) | [(1,056)](/filings/0001214659-25-013609.md) | [(3,400) d](/filings/0001214659-25-017793.md) | [(1,424) d](/filings/0001214659-26-003166.md) | [(689) d](/filings/0001214659-26-008832.md) | [(2,363)](/filings/0001214659-26-011572.md) | [(1,171) d](/filings/0001214659-25-017793.md) | [(1,736) d](/filings/0001214659-26-003166.md) | [(2,797) d](/filings/0001214659-26-008832.md) | [(1,139)](/filings/0001214659-26-011572.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q2 FY2023 (2022-10-31) | Q3 FY2023 (2023-01-31) | Q1 FY2024 (2023-07-31) | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [6,499](/filings/0001214659-23-016500.md) | [6,555](/filings/0001214659-24-005088.md) | [656](/filings/0001214659-24-016346.md) | [656](/filings/0001214659-24-020264.md) | [705](/filings/0001214659-25-004123.md) | [85.3](/filings/0001214659-25-013609.md) | [392](/filings/0001214659-25-017793.md) | [612](/filings/0001214659-26-003166.md) | [2,106](/filings/0001214659-26-011572.md) | [3,381](/filings/0001214659-25-017793.md) | [3,805](/filings/0001214659-26-003166.md) | [4,479](/filings/0001214659-26-011572.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,825,723 at 2026-09-10, from the cover of the [10-Q filed 2026-09-10](/filings/0001214659-26-011572.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.